preview of CHTC adpixel

Dr Afshin Safavi, Former Founder of BioAgilytix Labs and Current Founder of Colorado Health & Tech Centers, Joins Sqale’s Board of Directors

COPENHAGEN, Denmark – Sqale ApS, a Danish company innovating in biologics manufacturing by blending quantum-enhanced optimization, agile pipeline development, and cutting-edge manufacturing concept in its BioBox™️, announced today that Dr Afshin Safavi had been appointed to its Board of Directors. Dr Safavi, as the former founder of BioAgilytix Labs and current founder and CEO of Colorado Health & Tech Centers, brings in a long track record of successfully starting and scaling contract organizations and biotechnology companies from the start-up stage.

“I can’t adequately express our excitement to welcome Afshin to the Sqale’s Board of Directors,” said Dr. Seyed Soheil Mansouri, Co-Founder of Sqale. “Afshin comes to us with a wide range of experience and expertise as a founder, CEO, councilman, board member, scientist, entrepreneur, and investor in biotechnology, pharmaceutical, and other market sectors.  He has been instrumental in scaling multi-millions to multi-billion-dollar companies.”

Afshin Safavi, Founder and CEO of Colorado Health & Tech Centers, shared his enthusiasm about joining Sqale’s Board of Directors: “I am incredibly excited to join Sqale’s Board of Directors alongside its founders Christopher Savoie, Christian Beenfeldt, and Seyed Soheil Mansouri. Together, they are forming an exceptional team of founders. They are committed to revolutionizing biomanufacturing. This perfectly aligns with what I believe is needed in the biomanufacturing sector. Their presence will undoubtedly enrich biomanufacturing by applying emerging technologies to modernization and re-thinking of manufacturing processes from optimization across scales performed faster and in a more cost-effective manner.”

Cathal Mahon, Chief Business Officer at Deep Tech Lab – Quantum (DTL-Q) of BioInnovation Institute in Copenhagen commented on Dr Afshin Safavi joining the Sqale board: “The experience that Afshin brings along with his level of enthusiasm and World-wide connections will be very impactful for Sqale – a Danish startup company incubated at DTL-Q of BioInnovation Institute – to move faster toward becoming the premier biomanufacturing partner for many of the top pharma and biotechnology companies as well as drug innovators and vaccine developers”.

About Sqale

Sqale is revolutionizing biopharmaceutical manufacturing with our innovative approach, blending quantum-enhanced optimization, agile pipeline development, and cutting-edge manufacturing concept, BioBox™️. Our mission is to make treatments affordable for cancers, neurological disorders, and infectious diseases. Leveraging quantum-enhanced optimization, we streamline processes for efficiency and cost-effectiveness. Our agile pipeline development ensures rapid adaptation, accelerating research translation. With state-of-the-art manufacturing plants, we’re pioneering next-generation production techniques.

About Afshin Safavi

Dr. Afshin Safavi is a founder, consultant, board member, entrepreneur, and investor in biotechnology, pharmaceutical, animal health, technology, and real-estate sectors with multi-billion-dollar turnovers in biological products and is responsible for multiple drug products in the market today. He has founded Colorado Health and Tech Centers (CHTC), and BioAgilytix Labs, one of the most successful multi-billion-dollar Contract Research Organizations known internationally. Before founding Colorado Health and Tech Centers (CHTC), and BioAgilytix Labs, he worked for various organizations, including AAIPharma, Bayer Biologicals, Talecris BioTherapeutics (Grifols), Nobex Corporation, GlaxoSmithKline, and IGEN International. Dr. Safavi obtained his B.S. in Biochemistry from UCLA and his Ph.D. in Biochemistry from the University of Kentucky Medical School. He completed a two-year postdoctoral assignment at Emory University, Department of Pathology.

Contact: For more information about Sqale, Investment or Media Contact, please contact Jascha Jäger, at